斑秃新诊断患者的免疫介导与精神共病研究
该回顾性队列分析基于美国Merative MarketScan数据库2007至2023年数据,评估12-64岁斑秃患者精神与自身免疫共病的患病率及新发风险。结果显示斑秃诊断时精神共病(30.9% vs 26.8%)和自身免疫共病(16.1% vs 8.9%)患病率均更高,且新发精神(AHR 1.3;95%CI 1.3-1.4)和自身免疫(AHR 2.7;95%CI 2.5-2.8)共病风险显著升高。
要点
- 斑秃诊断时精神共病患病率30.9%,自身免疫共病患病率16.1%,均高于对照。
- 斑秃患者新发精神共病风险AHR 1.3(95%CI 1.3-1.4)。
- 斑秃患者新发自身免疫共病风险AHR 2.7(95%CI 2.5-2.8)。
核心结论
- 斑秃患者诊断时自身免疫和精神共病患病率更高,诊断后新发自身免疫和精神共病风险也升高。
研究设计与样本
- 回顾性队列分析,使用Merative MarketScan研究数据库2007年1月1日至2023年4月30日数据。
主要发现
- 与非匹配对照相比,斑秃患者诊断时精神共病患病率30.9% vs 26.8%(P < .001)。
- 与非匹配对照相比,斑秃患者诊断时自身免疫共病患病率16.1% vs 8.9%(P < .0001)。
- 与匹配对照相比,斑秃患者新发精神共病风险AHR 1.3(95%CI 1.3-1.4)。
- 与匹配对照相比,斑秃患者新发自身免疫共病风险AHR 2.7(95%CI 2.5-2.8)。
临床怎么用
- 数据提示应关注斑秃患者常见共病,可能有助于医生对新诊断斑秃患者进行咨询和监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alopecia areata (AA) has been associated with multiple comorbidities, yet information regarding the timing of comorbidity development after AA diagnosis is limited. OBJECTIVE: To evaluate the prevalence and new-onset incidence of psychiatric and autoimmune comorbidities in patients with AA in the US. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used data collected from January 1, 2007, to April 30, 2023, from the Merative MarketScan Research Databases, which contains medical and drug claims data from more than 46 million patients in the US. Data from adolescent and adult patients (aged 12-64 years) diagnosed with AA and patients without AA (ie, controls) were evaluated. For some analyses, patients with AA were matched (1:4) to controls based on sex, age, and geographic region. MAIN OUTCOMES AND MEASURES: Prevalence (at the time of AA diagnosis) and incidence (new onset after AA diagnosis) of psychiatric and autoimmune diseases were reported as percentage of patients. Risk of developing a new-onset psychiatric or autoimmune disease after AA diagnosis was calculated as adjusted hazard ratios (AHRs) with 95% CIs. RESULTS: At baseline, 63 384 patients with AA and 3 309 107 without AA were identified. After matching, there were 16 512 and 66 048 patients in the AA and control groups, respectively, with a mean (SD) age of 36.9 (13.4) years and 50.6% of whom were female. Compared with the unmatched controls, patients with AA had higher prevalence of psychiatric (30.9% vs 26.8%; P < .001) and autoimmune (16.1% vs 8.9%; P < .0001) comorbidities at AA diagnosis; incidence was also higher in patients with AA (without history of these comorbidities) vs the matched control group. Patients with AA vs controls had a significantly higher risk of developing a psychiatric (AHR, 1.3; 95% CI, 1.3-1.4) or autoimmune (AHR, 2.7; 95% CI, 2.5-2.8) comorbidity. CONCLUSIONS AND RELEVANCE: In this cohort study, patients with AA had a higher prevalence of autoimmune and psychiatric comorbidities at AA diagnosis and demonstrated an elevated risk of new-onset autoimmune and psychiatric comorbidities after their diagnosis. These data highlight the most common comorbidities among patients with AA and may help physicians counsel and monitor patients newly diagnosed with AA.
引用
- Mostaghimi A, Soliman AM, Li C, et al. Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata. JAMA Dermatol. 2024. PMID: 39083282. doi:10.1001/jamadermatol.2024.2404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。